垂体前叶内神经纤维可能参与ACTH分泌的调节

我们建立了垂体组织块短时温育并施加电场刺激的离体实验体系,运用此方法并结合放射免疫测定激素含量,观察了大鼠垂体前叶内神经纤维对促肾上腺皮质激素（ＡＣＴＨ）释放的影响。结果表明,电场刺激能够促使垂体前叶ＡＣＴＨ释放显著增加,刺激参数为强度３０ｍＡ,波宽０．５ｍｓ,频率１０Ｈｚ。这个效应可为温育液中加入河豚毒素（ＴＴＸ）和藜芦碱所阻断,但ＴＴＸ不能阻断精氨酸加压素（ＡＶＰ）诱发的ＡＣＴＨ分泌。同样参数的电场刺激对分散培养的大鼠垂体前叶细胞ＡＣＴＨ的分泌没有显著作用。以上结果说明,我们所用参数的电场刺激产生的效应是兴奋了垂体前叶内的神经纤维,而非直接刺激腺细胞所致。上述结果提示：垂体前叶激素分泌的调节除了传统的体液途径之外,还可能存在直接的神经控制。     

电场刺激对垂体前叶ACTH分泌的影响及作用机制的研究

目的和方法：本实验通过切除大鼠肾上腺改变垂体的功能状态,利用垂体组织块离体灌流并施加电场刺激的方法,观察服垂体前叶内神经纤维对促肾上腺皮质激素（ＡＣＴＨ）释放的影响,结果：参数为强度３０ｍＡ,波宽０．５ｍｓ,频率１０Ｈｚ的电场刺激可明显抑制肾上腺切除９６ｈ后垂体前叶组织块释放ＡＣＴＨ,此效应可被预先给予的河豚毒素（ＴＴＸ）所取肖精氨酸加压素（ＡＶＰ）可显著刺激垂体组织块释放ＡＣＴＨ,同样参数的电场     

葆包牡丹碱对垂体前叶组织块释放促肾上腺皮质激素的刺激效应

本实验利用垂体组织块离体灌流技术,观察到γ－氨基丁酸Ａ受体拮抗剂荷包牡丹笃切除双侧肾上腺９６ｈ后的大鼠垂体前叶ＡＣＴＨ的分泌具有强烈的刺激作用。但同样浓度的荷包牡丹笃分离的垂体前叶细胞的ＡＣＴＨ分泌无影响,提示肾上腺切除后,γ－氨基丁酸在垂体前叶直接或通过间接途径抑制ＡＣＴＨ分泌。     

荷包牡丹碱对垂体前叶组织块释放促肾上腺皮质激素的刺激效应

本实验利用垂体组织块离体灌流技术,观察到－氨基丁酸Ａ受体拮抗剂荷包牡丹碱对切除双侧肾上腺９６ｈ后的大鼠垂体前叶ＡＣＴＨ的分泌具有强烈的刺激作用。但同样浓度的荷包牡丹碱对分离的垂体前叶细胞的ＡＣＴＨ分泌无影响。提示肾上腺切除后,－氨基丁酸在垂体前叶直接或通过间接途径抑制ＡＣＴＨ分泌。     

神经内分泌讲座（六）：促肾上腺皮质激素释放激素

早在１９４８年,哈里斯（Ｈａｒｒｉｓ）就提出下丘脑含有调节垂体功能的化学递质。１９５５年,萨夫兰（Ｓａｆｒａｎ）和吉尔曼（Ｇｕｉｌｅｍｉｎ）等发现下丘脑提取物中存在着刺激腺垂体分泌促肾上腺皮质激素（ＡＣＴＨ）的物质,被命名为促肾上腺皮质激素释放因子（...     

中枢ACTH受体研究进展

除垂体以外,中枢神经系统也含有促肾上腺皮质激素（ＡＣＴＨ）能神经元,其神经纤维在中枢具有较广泛的投射。ＡＣＴＨ相关肽类在中枢发挥着多种生理功能。近年来对于中枢ＡＣＴＨ受体的研究取得很大的进展,现已确认ＡＣＴＨ结合位点在中枢具有广泛的分布。新近克隆出的四种ＡＣＴＨ受体中,有两种是中枢神经系统占优势的受体亚型。     

炎症介质在内毒素引起大鼠肠系膜血管床降钙素基因相关肽释放中的作用

本研究在离体大鼠肠系膜血管床灌流模型上,采用特异放免法测定灌流液中的降钙素基因相关肽（ＣＧＲＰ）,观察几种常见炎症介质在内毒素引起ＣＧＲＰ释放中的作用。结果显示：前列腺素合成酶抑制剂地塞米松、布洛芬与消炎痛,缓激肽受体Ｂ２拮抗剂ＨＯＥ１４０,血小板激活因子拮抗剂ＷＥＢ２０８６,组胺Ｈ１受体拮抗剂苯海拉明以及和组胺Ｈ２受体拮抗剂西咪替丁,均能明显抑剂制内毒素引起的ＣＧＲＰ释放,５羟色胺受体拮抗剂ＩＣＳ２０５９３０却无明显作用。从而提示：内毒素引起ＣＧＲＰ释放是通过炎症介质前列腺素、缓激肽、血小板激活因子和组胺介导的,阻断或减少炎症介质的产生可望减轻内毒素血症时ＣＧＲＰ的过量释放。     

大鼠垂体前叶中的TH-,ChAT-免疫阳性神经纤维

长期以来,人们一直认为垂体前叶腺细胞没有直接神经支配,前叶内只有自主神经纤维支配垂体前叶的血管。本文在大鼠垂体的相邻切片上,应用免疫组织化学技术,对前叶中的儿茶酚胺的特征性酶——酪氨酸羟化酶（ＴＨ）和乙酰胆碱的特征性酶——胆碱乙酰转移酶（ＣｈＡＴ）进行显色。结果显示,大鼠垂体前叶中存在着ＴＨ－和ＣｈＡＴ－免疫阳性神经终末,两者可同时分布于垂体前叶的同一区域,且有较多终末分布于腺细胞周围。本文提示：儿茶酚胺和胆碱能神经纤维有可能直接调节腺细胞的活动     

炎症介质在内毒素引起大鼠肠系膜血管床降钙素基因相关…

本研究在离体大鼠肠系膜血管床灌流模型上,采用特异放免法测定灌流液中的降钙素基因相关肽（ＣＧＲＰ）观察几种常见炎症介质在内毒素引起ＣＧＲＰ释放中的作用,结果显示：前列腺素合成酶抑制剂地塞米松,布洛芬与消炎痛,缓激肽受体Ｂ２拮抗剂ＨＯＥ－１４０,血小板激活因子拮抗剂ＷＥＢ２０８６,组胺Ｈ１受体拮抗剂苯海拉明以及和组胺Ｈ２受体拮抗剂西咪替丁,均能明显抑剂制内毒素引起的ＣＧＲＰ释放,５羟色胺受体拮抗剂ＩＣ     

中枢5—羟色胺能系统与下丘脑—垂体应激激素

存在于下丘脑的神经末梢所释放的５－羟色胺（５－ＨＴ）可增加ＣＲＨ和肾素释放因子、垂体前叶ＡＣＴＨ和催乳素（ＰＲＬ）、垂体后叶加压素（ＶＰ）和催产素（ＯＴ）的分泌。５－ＨＴ１和／或５－ＨＴ２受体激活介导了这些激素分泌。     

The met-enkephalin analog FK 33-824 directly inhibits ACTH release by the rat pituitary gland in vitro

Systematic administration of the enkephalin analog FK 33-824 was previously shown to stimulate PRL secretion and to inhibit ACTH secretion in man. Naloxone prevented the effect on PRL release, but not on ACTH release. In this study, the direct action of this analog on hormone release by rat anterior pituitary lobes $\text{in}$$\text{vitro}$ were investigated. 1 uM FK 33-824 inhibited basal ACTH secretion by anterior pituitary glands in vitro, while 0.1 uM and 1 uM attenuated the lysine vasopressin stimulated ACTH release. Naloxone did not reverse the inhibitory action of the analog on ACTH release. β-Endorphin (0.01 - 1 uM) did not directly affect ACTH release. Basal and dopamine-induced inhibition of PRL release by anterior pituitary glands was neither influenced by FK 33-824 (0.1 and 1 uM), nor by β-endorphin (0.1 and 1 uM) with or without bacitracin. This study shows that the long-acting met-enkephalin analog FK 33-824 differentially affects PRL and ACTH secretion by the pituitary gland. It seems to stimulate PRL release at a suprapituitary site and this action probably involves u opiate receptors, because naloxone prevents these stimulatory effects. The inhibitory effect of FK 33-824 on ACTH release, however, is mediated via a direct effect at the pituitary level, which does not involve u receptors, as naloxone did not prevent this effect. In this respect, its action differs from that of β-endorphin, which does not directly affect ACTH release by the anterior pituitary gland.     

Interactions between CRF, epinephrine, vasopressin and glucocorticoids in the control of ACTH secretion

The secretion of ACTH by corticotrophs in the anterior lobe of the rat pituitary gland is under the stimulatory influence of at least three receptors, namely that for peptidic CRF (corticotropin-releasing factor), vasopressin and alpha 1-adrenergic agents. CRF is a potent stimulator of cyclic AMP accumulation as well as adenylate cyclase activity in the rat adenohypophysis, thus suggesting an important role of cyclic AMP as mediator of CRF action on ACTH secretion. Vasopressin causes a 2-fold increase of the stimulatory effect of CRF on ACTH release in rat anterior pituitary cells in culture. The potentiating effects of vasopressin on CRF-induced ACTH release are accompanied by parallel changes of intracellular cyclic AMP levels. Vasopressin, while having no effect on basal cyclic AMP levels, causes a 2-fold increase in CRF-induced cyclic AMP accumulation without affecting the ED50 value of CRF action. ACTH secretion is also stimulated by a typical alpha 1-adrenergic receptor. Epinephrine causes a marked stimulation of ACTH release which is additive to that of CRF. Epinephrine, in analogy with vasopressin, although having no effect alone on basal cyclic AMP levels, causes a marked potentiation of CRF-induced cyclic AMP accumulation. Glucocorticoids cause a near-complete inhibition of epinephrine-induced ACTH secretion within 4 h with the following order of ED50 values: triamcinolone acetonide (0.2 nM) greater than dexamethasone (1.0 nM) much greater than cortisol (11 nM) greater than corticosterone (22 nM). Similar effects are observed for CRF- and vasopressin-induced ACTH release. Although the activity of the pituitary-adrenocortical axis in the rat is highly dependent upon sex steroids, 17 beta-estradiol, 5 alpha-dihydrotestosterone and the pure progestin R5020 have no detectable effect on basal or epinephrine-induced ACTH release, thus illustrating the high degree of specificity of glucocorticoids in their feedback control of ACTH secretion. Moreover, glucocorticoids have no effect on CRF-induced cyclic AMP accumulation, thus indicating that their inhibitory effect is exerted at a step following cyclic AMP accumulation.     

Cellular localization of apelin and its receptor in the anterior pituitary: evidence for a direct stimulatory action of apelin on ACTH release

Apelin is a bioactive peptide recently identified as the endogenous ligand of the human orphan G protein-coupled receptor APJ. The presence of apelin-immunoreactive nerve fibers, together with the detection of apelin receptor mRNA in the parvocellular part of the paraventricular nucleus and the stimulatory action of apelin on corticotropin-releasing hormone release, indicate that apelin modulates adrenocorticotropin (ACTH) release via an indirect action on the hypothalamus. However, a direct action of apelin in the anterior pituitary cannot be excluded. Here, we provided evidence for the existence of an apelinergic system within the adult male rat pituitary gland. Double immunofluorescence staining indicated that apelin is highly coexpressed in the anterior pituitary, mainly in corticotrophs (96.5 +/- 0.3%) and to a much lower extent in somatotropes (3.2 +/- 0.2%). Using in situ hybridization combined with immunohistochemistry, a high expression of apelin receptor mRNA was also found in corticotrophs, suggesting a local interaction between apelin and ACTH. In an ex vivo perifusion system of anterior pituitaries, apelin 17 (K17F, 10(-6) M) significantly increased basal ACTH release by 41%, whereas apelin 10 (R10F, 10(-6) M), an inactive apelin fragment, was ineffective. In addition, K17F but not R10F induced a dose-dependent increase in K(+)-evoked ACTH release, with maximal increase being observed for a 10(-6) M concentration. Taken together, these data outline the potential role of apelin as an autocrine/paracrine-acting peptide on ACTH release and provide morphological and neuroendocrine basis for further studies that explore the physiological role of apelin in the regulation of anterior pituitary functions.     

Growth hormone-releasing peptide-2 stimulates secretion and synthesis of adrenocorticotropic hormone in mouse pituitary

Growth hormone (GH)-releasing peptides (GHRPs) are synthetic peptides which induce strong GH release in both animals and humans. Among them, GHRP-2 is known to stimulate GH release by acting at both hypothalamic and pituitary sites, but also induces adrenocorticotropic hormone (ACTH) release in healthy subjects. GHRP-2 may stimulate ACTH release directly via GHRP receptor type 1a in ACTH-producing tumors. GHRP-2 increases ACTH secretion in rat in vivo, but not ACTH release from rat primary pituitary cells. In the present study, in order to elucidate the mechanism underlying ACTH secretion by GHRPs, mouse pituitary cells were stimulated by GHRP-2. GHRP receptor mRNA was expressed in the mouse pituitary, and GHRP-2 directly stimulated secretion and synthesis of ACTH in the mouse anterior pituitary cells. GHRP-2 increased intracellular cyclic AMP production. H89, a potent protein kinase A (PKA) inhibitor, and bisindolylmaleimide I, a selective protein kinase C (PKC) inhibitor, inhibited the GHRP-2-induced ACTH release, and that H89, but not bisindolylmaleimide I, inhibited the GHRP-2-induced proopiomelanocortin mRNA levels. Together, the GHRP-2-induced ACTH release was regulated via both PKA and PKC pathways in the mouse pituitary cells, while ACTH was synthesized by GHRP-2 only via the PKA pathway.     

Effect of calcitonin gene-related peptide on glucose and gastric inhibitory polypeptide-stimulated insulin release from cultured newborn and adult rat islet cells

Calcitonin gene-related peptide (CGRP) is a 37-amino acid peptide that is present in peripheral cells of islets and in nerves around and within islets. CGRP can inhibit insulin secretion in vitro and in vivo. Whether the inhibitory action of CGRP is mediated by somatostatin or by nerve terminals is, however, not known. The objective of this study was to examine the effect of CGRP on insulin secretion, using cultured newborn and adult rat islet cells which did not contain nerve terminals. In adult rat islet cells, CGRP (10(-10) to 10(-8) M) significantly inhibited glucose-stimulated and gastric inhibitory polypeptide (GIP)-potentiated insulin secretion, but in newborn rat islet cells, CGRP did not inhibit glucose-stimulated insulin secretion. Inhibition of glucose-stimulated and GIP-potentiated insulin release was dependent on the glucose concentration during the prestimulation period. CGRP did not stimulate release of somatostatin. These findings suggest that rat CGRP can act directly on beta-cells through a specific receptor that is absent in newborn rat beta-cells.     

Vasopressin and "CRF" in the regulation of ACTH secretion by the anterior and intermediate lobes of the pituitary gland (author's transl)

The aim of this review was to summarize the present state of knowledge concerning the mode of action of vasopressin (VP) and the putative corticotropin releasing factor (CRF) on ACTH secretion from the anterior and intermediate lobes of the pituitary gland. In vitro data show that although both CRF and VP enhanced release of anterior pituitary ACTH, the pattern of hormonal release, based on kinetical and dose-dependent studies, appeared to be different. Also, the effect of VP most probably was mediated by specific putative receptor sites. In contrast, VP was found not to alter ACTH secretion from the intermediate lobe; that secretion seems to be regulated by CRF-like material and neurotransmitters. The importance of VP as a corticotropin agent is discussed.